Agios Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Agios Pharmaceuticals, Inc.

Jul-30	Agios Reports Second Quarter 2026 Financial Results and Provides Business Update AGIO -6.46% GlobeNewswire
Jul-21	Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease AGIO -6.74% GlobeNewswire
Jul-07	U.S. FDA Grants Priority Review to Agios' sNDA for Mitapivat in Sickle Cell Disease AGIO +17.71% GlobeNewswire
Jun-29	Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET AGIO GlobeNewswire
Jun-13	Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease AGIO GlobeNewswire
Jun-01	Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib AGIO GlobeNewswire
May-29	Agios Provides Update on Phase 2b Trial of Tebapivat in Lower-Risk Myelodysplastic Syndromes AGIO GlobeNewswire
May-22	Agios' PYRUKYND (mitapivat) Approved in the European Union for Adults with Thalassemia AGIO GlobeNewswire
May-12	Agios Submits sNDA to FDA for U.S. Accelerated Approval of Mitapivat in Sickle Cell Disease AGIO GlobeNewswire
May-12	Agios to Present New Data at EHA 2026 Reinforcing the Significant Therapeutic Impact of Mitapivat Across Multiple Rare Hemolytic Anemias AGIO GlobeNewswire
Apr-29	Agios Reports First Quarter 2026 Financial Results and Provides Business Update AGIO +13.10% GlobeNewswire
Apr-06	Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET AGIO GlobeNewswire
Mar-31	Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA AGIO +14.25% GlobeNewswire
Mar-02	Agios' PYRUKYND (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates AGIO GlobeNewswire
Feb-12	Agios Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update AGIO GlobeNewswire
Jan-26	Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET AGIO GlobeNewswire
Jan-12	Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth AGIO GlobeNewswire
Jan-05	Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 AGIO GlobeNewswire
Dec-23	U.S. FDA Approves Agios' AQVESME (mitapivat) for the Treatment of Anemia in Adults with Alpha- or Beta-Thalassemia AGIO +18.63% GlobeNewswire
Dec-08	Agios Provides Update on U.S. sNDA for Mitapivat in Thalassemia AGIO GlobeNewswire
Nov-19	Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease AGIO -50.89% GlobeNewswire
Nov-03	Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition AGIO -7.19% GlobeNewswire
Oct-30	Agios Reports Third Quarter 2025 Financial Results and Provides Business Update AGIO GlobeNewswire
Oct-17	Agios' PYRUKYND (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia AGIO GlobeNewswire
Oct-16	Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET AGIO GlobeNewswire
Sep-04	Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND (mitapivat) in Thalassemia AGIO -11.03% GlobeNewswire
Aug-04	Agios' PYRUKYND (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia AGIO GlobeNewswire
Jul-31	Agios Reports Second Quarter 2025 Financial Results and Provides Business Update AGIO GlobeNewswire
Jul-14	Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET AGIO GlobeNewswire
Jul-08	Agios Appoints Dr. Jay Backstrom to Board of Directors AGIO GlobeNewswire
May-28	Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025 AGIO GlobeNewswire
May-14	Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress AGIO GlobeNewswire
May-09	Agios to Present at the 2025 RBC Capital Markets Global Healthcare Conference on May 21, 2025 AGIO GlobeNewswire
May-02	Agios to Present at the BofA Securities 2025 Health Care Conference on May 14, 2025 AGIO GlobeNewswire

Agios Pharmaceuticals, Inc.

Recent Articles by Agios Pharmaceuticals, Inc.

Upgrade your Finviz experience